

TABLE OF CONTENTS

FRONT COVER..... i

IMAGE COVER PAGEii

DEGREE REQUIREMENTiii

FORM OF APPROVAL.....iv

ACKNOWLEDGEMENT v

ABSTRACT.....vi

TABLE OF CONTENTS.....vii

LIST OF TABLES x

LIST OF FIGURESxi

GLOSSARYxii

CHAPTER I INTRODUCTION..... 1

 1.1 Background 2

 1.2 Research Question 2

 1.3 Objectives of Study..... 2

 1.3.1 General Objectives..... 2

 1.3.2 Specific Objectives 2

 1.4 Significance of Study..... 2

 1.4.1 Theoretical Significance 2

 1.4.2 Practical Significance 2

CHAPTER II LITERATURE REVIEW 3

| | |
|--|----|
| 2.1 Trigeminal Neuralgia | 3 |
| 2.1.1 Definition..... | 3 |
| 2.1.2 Epidemiology..... | 4 |
| 2.1.3 Pathophysiology | 4 |
| 2.1.4 Clinical Presentation..... | 5 |
| 2.1.5 Prognosis..... | 6 |
| 2.1.6 Treatment..... | 7 |
| 2.2 Medication Aspect | 9 |
| 2.2.1 Gold Standard Treatment..... | 9 |
| 2.2.2 Pharmacology of Carbamazepine | 9 |
| 2.2.3 NRS Pain Scale..... | 10 |
| CHAPTER III CONCEPTUAL FRAMEWORK AND HYPOTHESIS..... | 11 |
| 3.1 Conceptual Framework | 11 |
| 3.2 Conceptual Framework Discussion | 12 |
| CHAPTER IV METHOD OF RESEARCH | 13 |
| 4.1 Study Design | 13 |
| 4.2 Population and Sample | 13 |
| 4.2.1 Population | 13 |
| 4.2.2 Sample | 13 |
| 4.2.3 Sample Criteria | 13 |
| 4.2.3.1 Inclusion..... | 13 |
| 4.2.3.2 Exclusion | 13 |
| 4.3 Variable and Operational Variable Definition | 14 |

| | |
|--|----|
| 4.3.1 Independent and Dependent Variable..... | 14 |
| 4.3.2 Operational Variable Definition | 14 |
| 4.4 Location and Time Research | 15 |
| 4.4.1 Location of Research | 15 |
| 4.4.2 Time of Research | 15 |
| 4.5 Data Collection Techniques | 15 |
| 4.6 Data Analysis..... | 15 |
| 4.7 Ethical Eligibility Clearance..... | 15 |
| CHAPTER V RESULTS | 16 |
| 5.1 Results | 16 |
| 5.1.1 Sex Distribution | 17 |
| 5.1.2 Age Distribution | 17 |
| 5.2 Pharmacotherapy Profile | 18 |
| 5.2.1 Analgesic Therapy Distribution | 18 |
| 5.2.2 Distribution of Vitamin B in Pharmacotherapy | 19 |
| 5.3 Pain Scale | 20 |
| 5.3.1 Patient Pain Scale Distribution..... | 20 |
| 5.3.2 Distribution of Pain Scale Before and After Treatment..... | 21 |
| CHAPTER VI DISCUSSION | 23 |
| 6.1 Demographics Data | 23 |
| 6.2 Pharmacotherapy Profile | 24 |
| 6.2.1 Pharmacotherapy of Carbamazepine..... | 24 |
| 6.2.2 Pharmacotherapy of Carbamazepine and Amitriptyline | 26 |
| 6.2.3 Pharmacotherapy of Carbamazepine and PDA..... | 26 |
| 6.2.4 Pharmacotherapy of Carbamazepine and Diclofenac | 27 |

| | |
|--|----|
| 6.2.5 Pharmacotherapy of Carbamazepine and Dexamethasone | 28 |
| 6.2.6 Pharmacotherapy of Carbamazepine and Gabapentin | 28 |
| 6.2.7 Pharmacotherapy of Gabapentin | 29 |
| 6.2.8 Pharmacotherapy of Gabapentin and Paracetamol..... | 30 |
| 6.2.9 Pharmacotherapy of Gabapentin and Diclofenac..... | 30 |
| 6.2.10 Pharmacotherapy of PDA, PDAC, IDA..... | 31 |
| 6.2.11 Pharmacotherapy of Phenytoin | 32 |
| 6.2.12 Pharmacotherapy of Phenytoin and Diclofenac | 33 |
| 6.2.13 Pharmacotherapy of Pregabalin and Diclofenac | 33 |
| 6.2.14 Pharmacotherapy of Paracetamol..... | 34 |
| 6.2.15 Pharmacotherapy of Diazepam | 35 |
| 6.2.16 Pharmacotherapy of Valproic Acid..... | 36 |
| 6.2.17 Pharmacotherapy of Amitriptyline..... | 37 |
| 6.2.18 Pharmacotherapy of Diclofenac Sodium..... | 38 |
| 6.2.19 Pharmacotherapy of Caffeine..... | 40 |
| | |
| 6.3 Role of Vitamin B | 41 |
| 6.3.1 Role of Vitamin B1 | 41 |
| 6.3.2 Role of Vitamin B6 | 42 |
| 6.3.3 Roles of Vitamin B12..... | 42 |
| 6.3.4 Mecobalamin..... | 42 |
| 6.3.5 Synergy of Neurotrophic B Vitamin | 43 |
| 6.4 Pain Scale | 44 |
| 6.4.1 General Characteristics of Pain Distribution..... | 44 |

| | |
|--|----|
| 6.4.2 Pharmacotherapy Regiments and Pain Scale | 44 |
| CHAPTER VII CONCLUSION AND SUGGESTION | 47 |
| 7.1 Conclusion..... | 47 |
| 7.2 Discussion..... | 48 |
| REFERENCE | 49 |

LIST OF TABLES

| | |
|---|----|
| Table 4.3 Variable and Operational Variable Definition | 12 |
| Table 5.1 Age Distribution of Trigeminal Neuralgia Patients | 17 |
| Table 5.2 Distribution of NRS Data | 20 |
| Table 5.3 Distribution of Pain Scale Before and After Treatment | 21 |

LIST OF FIGURES

Figure 3.1 Conceptual Framework 11
Figure 5.1 Distribution of Sex Ratio in Trigeminal Neuralgia Patients 16
Figure 5.2 The Distribution of Analgesic Therapy Received by Trigeminal
Neuralgia Patients..... 18
Figure 5.3 The Distribution of Vitamin B within Total Patients 19
Figure 5.5 Patient Pain Scale Before and After Treatment 22

GLOSSARY

| | |
|-------|---|
| RSUD | : Rumah Sakit Umum Daerah |
| IHS: | : International Headache Society |
| TN: | : Trigeminal Neuralgia |
| NINDS | : National Institute of Neurological Disorders and Stroke |
| CBZ | : Carbamazepine |
| OXC | : Oxcarbamazepine |
| GBP | : Gabapentin |
| PDA | :Paracetamol Diazepam Amitriptyline |
| PDAC | :Paracetamol Diazepam Amitriptyline Caffeine |
| IDA | :Ibuprofen Diazepam Amitriptyline |
| PHN: | :Phenytoin |
| PGB: | Pregabalin |
| NPRS | : Numerical Pain Rating Scale |
| MCID | : Minimally Clinically Important Differences |